Incasitolide A extracted from *Carpesium cernuum* induces apoptosis *in vitro* via the PI3K/AKT pathway in benign prostatic hyperplasia

Xiaoyue Chen\(^1\), Jingrui Song\(^2\), Dongbo Yuan\(^1\), Qing Rao\(^2\), Kehua Jiang\(^1\), Shuhui Feng\(^4\), Guohua Zhu\(^1\), Chen Yan\(^4\)*, Yanmei Li\(^2\)*, Jianguo Zhu\(^1,3\)*

\(^1\)Department of Biomedicine, Guizhou University, Guiyang, 550002, P.R. China.

\(^2\)State key laboratory of functions and applications of medicinal plants, Guizhou medical university, Guiyang, 550014, China;

\(^3\)Guizhou provincial people’s hospital, Guiyang, 550002, P.R. China;

\(^4\)An Shun City People’s Hospital, Anshun 561000, P.R. China.

\(^*\)Correspondence: zhujinguodoctor@163.com (J.G. Zhu); liyanmei518@hotmail.com (Y.M. Li); 12992636@qq.com (C. Yan)

The institutional email address: Guizhou provincial people’s hospital (5055cn@163.com)

**Phone number of the institution:** 0851-85922979

**Abstract**

Benign prostatic hyperplasia (BPH) is a common disease that occurs mainly in older men. The pathogenesis of BPH is complex and patients face a prolonged treatment course, and novel drugs with better selectivity and lower toxicity are required. incasitolide A (compound TMJ-12) is a germacrane-type sesquiterpenoid compound extracted from the plant *Carpesium cernuum*. Extracts of *C. cernuum* are known to exert suppressive effects on BPH-1 cells. In this study, we investigated the molecular mechanisms underlying the suppressive effect of TMJ-12 specifically on BPH-1 cells. A cytotoxicity assay indicated that TMJ-12 inhibited BPH-1 cell proliferation, while flow cytometry assays showed that TMJ-12 induced G2/M phase cell cycle arrest and the apoptosis of BPH-1 cells. TMJ-12 was also shown to regulate the expression of several apoptosis- and cell cycle-related proteins, namely Bcl-2, Bax, Bad, Caspase-9, Caspase-3, CDK1, Cyclin B1, CDC25C, and c-Myc, among others. Collapse of the mitochondrial membrane potential (ΔΨm) following exposure to TMJ-12 was detected with the JC-1 staining assay. Further investigation revealed that treatment with TMJ-12 inhibited the PI3K/AKT pathway by increasing the...
expression of PTEN. Taken together, the results suggest that TMJ-12 prevents BPH-1 cell proliferation via the PI3K/AKT pathway by inducing apoptosis and cell cycle arrest.

**Keywords:** inacspitolide A; *Carpesium cernuum*; benign prostatic hyperplasia; apoptosis; cell cycle; PI3K/AKT pathway

**Introduction**

Benign prostatic hyperplasia (BPH) is a non-malignant enlargement of the prostate[1]. It is a common disease among older men, with up to 80% reported to have some degree of prostate enlargement by the age of 50 years[2]. The symptoms of BPH can be obstructive or irritative or may only affect the patient after micturition. Current treatments for BPH include surgery to resect the obstructive prostate tissue and minimize disease progression, or medications such as the 5-alpha reductase inhibitors, epristeride and finasteride, which blocks the conversion of testosterone to DHT, inhibiting prostatic hyperplasia, reducing prostate size, and slowing disease progression[3]. However, since most BPH patients are elderly, most of them may have serious cardiovascular and cerebrovascular complications and cannot be treated with surgery[4]. Many men are plagued with abhorrent side effects such as erectile dysfunction, ejaculatory problem and a decrease in libido. Of note, high post void residuals, dry mouth, constipation, and the risk of dementia limits their long-term use in the elderly[5,6]. While Natural molecule compounds have milder effects and less adverse reactions, so they are suitable for long-term use[7]. BPH can severely affect the health and well being of patients, and novel drugs with better selectivity and lower toxicity are required. Drugs for the treatment of BPH mainly act by inhibiting prostate cell proliferation.

The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is crucial to many aspects of cell growth and survival, and the abnormal activation of the PI3K/AKT signaling pathway is associated with the occurrence and development of oncogenic effects[8]. PI3K is a heterodimer consisting of a catalytic subunit (p110) and a regulatory subunit (p85). Upon activation, PI3Ks phosphorylate phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P_2] to produce PtdIns(3,4,5)P_3 [9]. AKT (protein kinase B) is the primary downstream mediator of the effects of PI3K. AKT is activated by phosphorylation at Thr308 by 3-phosphoinositide-dependent protein kinase 1 (PDK1)
and at Ser473 in the hydrophobic C-terminal domain by PDK2. Abnormal levels of AKT can affect the expression of proteins regulating various cell cycle-dependent kinases, such as cyclin-dependent kinase 1 (CDK1) and CDK2, thereby affecting cell cycle regulation and causing cell cycle arrest[10,11]. Phosphorylated AKT can promote the phosphorylation of mTORC1 directly or indirectly. The mTORC1 protein complex activates the downstream eukaryotic initiation factor 4E-binding protein 1 (4EBP1) and ribosomal p70S6 kinase (p70S6K), which participate in cell cycle regulation and cell apoptosis[12,13]. The PI3K/AKT pathway can inactivate the Caspase-9 and Caspase-3 proteins, and at the same time, affect the binding of Bad and Bcl-2, thereby inhibiting cell apoptosis[14]. The phosphatase and tensin homolog deleted on chromosome 10 (PTEN), which can convert PtdIns (3,4,5) P3 to PtdIns (4,5) P2, is a negative regulator of the PI3K/AKT pathway[15,16].

_Carpesium cernuum_, which belongs to the genus _Carpesium_ (Asteraceae), is traditionally used to treat fevers, colds, bruises, and inflammatory diseases[17]. The constituents of this plant have been previously investigated and shown to contain several sesquiterpenoids with diverse bioactivities such as cytotoxicity, anti-inflammatory, and antifungal activities[18]. In recent years, sesquiterpenoids have served as a major source of lead compounds for the development of drugs targeting tumor cells[19]. In the early stage, when we checked the literature found that the crude drug _Carpeium cernuum_ extract has the effect of inhibiting the BPH1 cells, but the author did not elaborate on its mechanism[20]. Therefore, our group has isolated and extracted the main component of _Carpeium cernuum_, incaspitolide A, and conducted cytotoxicity experiments and mechanism research. The compound incaspitolide A (termed TMJ-12 in this study, see Figure 1A) is one such sesquiterpenoid isolated from _C. cernuum_[21]. The purity analysis of TMJ-12 were described as supplementary data 1. In the present study, we investigated the effect of TMJ-12 on a benign prostatic hyperplasia cell line (BPH-1) and found that it induced apoptosis and cell cycle arrest by activating PI3K/AKT signaling.

**Materials and Methods**

**Extraction of TMJ-12**
Main extraction, isolation, and purification Process of TMJ-12 were described as before [21]. Incaspitolide A was obtained from fraction-5 (Fr. 5), Fr. 5 (82.0 g) was chromatographed on a silica gel column (petroleum ether–ethyl acetate from 9:1 to 5:5) to give Sub-fraction 5e was subjected to CC over silica gel (petroleum ether–ethyl acetate from 9:1 to 8:2) to obtain three fractions (5e-1, 5e-2, and 5e-3), 5e-3 were then separated using a Waters X-Bridge C18 column (4.6 × 250 mm) (MeCN/H2O = 50:50) to afford TMJ-12 (32.6 mg). Its NMR data is as follows: 

$^1$H-NMR (400MHz, CDCl3) δ: 6.38 (1H, d, J = 1.2 Hz, H-13a), 5.92 (1H, d, J = 1.2 Hz, H-13b), 4.82 (1H, d, J = 11.2 Hz, H-6), 6.43 (1H, dd, J = 1.2, 6.0 Hz, H-9), 4.59 (1H, d, J = 6.0 Hz, H-8), 3.45 (1H, dd, J = 1.6, 11.2 Hz, H-7), 3.03 (1H, m, H-4), 1.12 (3H, s, H-14), 1.01 (3H, d, J = 6.8 Hz, H-15), 13C NMR (100 MHz, CDCl3) δ: 25.1 (C-1), 33.0 (C-2), 35.4 (C-3), 73.2 (C-4), 77.2 (C-5), 71.0 (C-6), 45.2 (C-7), 78.2 (C-8), 211.1 (C-9), 41.7 (C-10), 132.6 (C-11), 168.4 (C-12), 126.7 (C-13), 20.3 (C-14), 22.0 (C-15), 2 iBu (176.8, 175.1, 33.80, 33.77, 18.9, 18.8, 18.7). It was identified as incaspitolide A by comparison of the physical and spectral data with the literature [22]. Its purity is 98.65% by HPLC analysis.

Reagents

Fetal bovine serum (FBS) was purchased from Gibco (Gaithersburg, MD, USA). Dulbecco’s Modified Eagle’s Medium (DMEM), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (USA). The Annexin V-FITC Apoptosis Detection Kit and Hoechst Staining Kit were purchased from Solarbio (Beijing, China).

Antibodies

Bax (ab32503; 1:1000), Bcl-2 (ab32124; 1:2000), CDK1 (ab201008; 1:1000), Cyclin B1 (ab32053; 1:10000), Cyclin D1 (ab40754; 1:2000), CyclinD2 (ab207604; 1:1000), c-Myc (ab32072; 1:1000), Cytochrome C (ab133504; 1:10000), RAS (ab52939; 1:1000), P27 (ab32034; 1:5000), P21 (ab109520; 1:1000) and PDK1 (ab202468; 1:2000) were obtained from Abcam (Cambridge, UK). Antibodies for Bad (9268S; 1:1000), Caspase-3 (9662S; 1:1000), cleaved Caspase-3 (9664; 1:1000), Caspase-9 (32539; 1:1000), PARP (9532; 1:1000), CDC25C (4688S; 1:1000), p-CDC25C (4901; 1:1000), PCNA (13110; 1:1000), P53 (2527S; 1:1000), PTEN (9188;
1:1000), AKT (4685; 1:1000), p-AKT (4060; 1:2000), mTOR (2983; 1:1000), p-mTOR (5536; 1:1000), EIF4E (2067; 1:1000), SAPK/JNK (9252; 1:1000), p-SAPK/JNK (9255; 1:1000), MAPK/P38 (8690; 1:1000), and p-MAPK/P38 (4511; 1:1000) were obtained from Cell Signaling Technology (Beverly, MA, USA).

**Cell culture**

The benign prostatic hyperplasia cell line (BPH-1) was a gift from the Sunnybrook Research Institute (Toronto, ON, Canada). The cells were cultivated in DMEM supplemented with 10% FBS and 1% (w/v) penicillin (Solarbio) at 37°C in a CO₂ incubator (5% CO₂, 95% humidity). After a 24 h incubation, the cells were treated with TMJ-12 at various concentrations (2, 4, 8, 12, or 16 μM) and the cells were then collected within the specified time for further analysis.

**Cytotoxicity assay**

The cytotoxicity of TMJ-12 toward the BPH-1 cell line was measured with the MTT assay according to a protocol previously described[22]. Briefly, cells were seeded in 96-well plates at a density of $1 \times 10^4$ cells/well, incubated at 37°C for 24 h, and then treated with TMJ-12 (0, 2, 4, 8, 12, 16 μM) for the indicated time (24 h or 48 h). Next, 20 μL of the MTT solution (5 mg/mL) was added to each well, and the plates were incubated for 4 h at 37°C. The resultant formazan crystals were dissolved in 160 μL of DMSO and the absorbance at 490 nm was measured using a spectrophotometer (Varioskan Flash; Thermo Fisher Scientific, Waltham, MA USA). The half-maximal inhibitory concentration (IC₅₀) of TMJ-12 toward the BPH-1 cells was calculated using a cell survival curve, and a growth curve was generated based on the absorbance and concentration values.

**Colony formation assay**

BPH-1 cells were seeded in 6-well culture plates at a confluency of $3 \times 10^5$ cells/plate, and the cells were then treated with various concentrations of TMJ-12 (0–16 μM) for 24 h. The cells were trypsinized, resuspended in the medium, and counted. Next, the cells were re-seeded (1000 cells per medium plate) and incubated for 20 days with fresh medium added every 4 days. The cells were then fixed with 4% paraformaldehyde for 30 min and stained with Crystal Violet.
Staining Solution (Beyotime, Jiangsu, China) for 15 min before counting.

**Cell apoptosis assay and cell cycle analysis**

The cell apoptosis assay and cycle analysis were performed with a FACS Calibur flow cytometer (BD Biosciences, NJ, USA). Propidium iodide (PI; Solarbio) was used for cell cycle analysis, while a staining kit containing annexin V-fluorescein isothiocyanate (annexin V-FITC) and PI (BD Pharmingen, San Diego, CA, USA) was used to assess cell apoptosis. BPH-1 cells (3 × 10^5) were seeded in six-well plates for 24 h and then incubated with TMJ-12 (0, 8, or 16 µM) for 24 h or 48 h. Next, the cells were washed with cold phosphate-buffered saline (PBS) and then fixed with chilled 75% ethanol overnight at −20°C. After being centrifuged at 1,000 rpm for 5 min, the cells were washed with chilled PBS. For cell cycle analysis, the cells were stained with PI for 30 min at 37°C and analyzed on the flow cytometer. For the apoptosis experiment, the cells were resuspended in chilled PBS and then incubated with 5 µL of the PI and annexin V-FITC kit reagents for 15 min at room temperature in the dark before being subjected to flow cytometry. Each experiment was performed in triplicate.

**Hoechst 33258 staining**

Cells were seeded in a 6-well plate at an initial density of 6 × 10^5 cells/well and treated with different concentrations of TMJ-12 (0, 8, and 16 µM) for 48 h. The cells were then collected and washed twice with PBS, and chromatin condensation was detected using the Hoechst 33258 Staining Kit (Beyotime). Stained nuclei were immediately photographed under a fluorescence microscope.

**Detection of the mitochondrial membrane potential (ΔΨm)**

The mitochondrial membrane potential of the cells was measured using the JC-1 assay (Beyotime). BPH-1 cells were seeded in 6-well plates (3 × 10^5 cells/well) and incubated at 37°C for 24 h. Next, the cells were treated with different concentrations of TMJ-12 (0, 8, and 16 µM) for 48 h, after which, the cells were collected and incubated with 10 mM JC-1 in the dark at 37°C for 30 min. Finally, JC-1 fluorescence was measured using the fluorescence microscope (BD Biosciences, NJ, USA).
Western blotting

After the BPH-1 cells had been treated with TMJ-12 (0,8,16 μM) for 24 h, the cells were collected, washed twice with ice-cold PBS, and lysed in RIPA buffer containing 1% (w/v) of a PMSF protease inhibitor (Solarbio) at 4°C for 30 min. Cell debris was removed by centrifugation at 12,000 rpm for 20 min at 4°C, and the protein concentrations were determined with the BCA Protein Assay Kit (Solarbio). Proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred by western blotting to nitrocellulose membranes. The membranes were blocked with 5% non-fat milk for 2 h, incubated overnight with primary antibodies at 4°C, and then incubated with a fluorescently labeled goat anti-rabbit IgG secondary antibody (Cell Signaling Technology, Danvers, MA, USA) for 2 h at room temperature. GAPDH was used as an internal control. Immunoreactive proteins were visualized with the Odyssey Infrared Imaging System (LI-COR Biotechnology, Lincoln, NE, USA) and densitometry analyses of the western blot bands were performed with ImageJ software.

Molecular docking

The protein structure of PTEN (PDB ID: 1D5R) required for docking was obtained from the PDB database (https://www.rcsb.org/). AutoDockTools 1.5.6 software[23] was used to remove the water molecules, perform hydrogenation, and calculate the charge of the protein. The structure was then saved in the pdbqt format. Subsequently, the Autodock Vina[24] program was used for molecular docking with the parameters set at num_modes = 10, energy_range = 4, and exhaustiveness = 100.

Statistical analysis

All data are expressed as the mean ± standard deviation (SD) of at least three independent experiments. Each experiment was repeated in triplicate. Statistical analyses were performed with Student’s t-test or one-way analysis of variance. Significance levels were defined as follows: not significant (ns), *P < 0.05; **P < 0.01; ***P < 0.001.

Results
Effect of TMJ-12 on BPH-1 cell viability

To investigate the effect of TMJ-12 on the viability of the BPH-1 cells, the MTT assay was performed on BPH-1 cells treated with increasing concentrations of TMJ-12 (0–16 μM) for 24, 48, or 72 h (Figure 1B). TMJ-12 was found to reduce BPH-1 cell viability in both a dose-dependent and time-dependent manner. The IC50 of TMJ-12 toward the BPH-1 cells was 8.02 μM after 72 h of incubation (Figure 1C). TMJ-12 treatment was also observed to induce noticeable morphological changes in these cells (Supplementary Figure 1). The colony formation assay was used to further assess the effects of TMJ-12 on BPH-1 cell proliferation (Figure 1D, E). Increasing concentrations of TMJ-12 (0–16 μM) were found to reduce the rate of colony formation of the BPH-1 cells in a dose-dependent manner.

TMJ-12 induces G2/M phase cell cycle arrest of BPH-1 cells

Since TMJ-12 inhibited BPH-1 cells proliferation, we further examined whether TMJ-12 effects BPH-1 on cell cycle progression. The treatment of BPH-1 cells with various concentration of TMJ-12 (8 μM or 16 μM) for 24 and 48 h respectively, and cell cycle distribution was determined by PI staining using flow cytometry. With the increase of TMJ-12 concentration and the prolongation of treatment time, the result indicated that TMJ-12 treatment led to a marked increase of cells at G2/M phase (Figure 2A).

To understand the underlying molecular events, we examined numerous cell cycle regulators. Western blot analyses revealed that the cell cycle family proteins CDK1, CyclinB1, CyclinD1, c-Myc, and the CDC25C were consistently declined in treated with TMJ-12 cells (Figure 2B). One of most improtent protein was CDC25C, which was critical for the G2 checkpoint. While the P27kip, P21cip and P53 were substantially elevated. In addition, proliferating cell nuclear antigen (PCNA), a downstream marker of proliferation, was remarkably downregulated in TMJ-12 treated cells (Figure 2C). Thus, our result showed that effect of TMJ-12 inhibited BPH-1 cell viability was related to cell cycle arrest.

TMJ-12 induces BPH-1 cell apoptosis via the mitochondrial apoptotic pathway

Apoptosis is a form of programmed cell death and mitochondrial changes are considered to be a hallmark of apoptosis[25]. Here, double-staining with annexin V-FITC and PI was employed
to analyze the rate of apoptosis of the BPH-1 cells following TMJ-12 treatment, while Hoechst 33258 staining was used to visualize the cell death caused by TMJ-12. Treatment of the BPH-1 cells with TMJ-12 (8 µM or 16 µM) for 24 h or 48 h was shown to induce apoptosis (Figure 3A, B), particularly in the high-dose groups. Following 48 h of treatment with TMJ-12 at 16 µM, 52.51% of the BPH-1 cells were observed to have undergone apoptosis.

Next, the JC-1 staining assay was used to investigate whether TMJ-12-induced apoptosis is mediated by the mitochondrial pathway. Compared with the untreated cells, treatment with 8 µM or 16 µM TMJ-12 for 24 h caused a dose-dependent increase in the JC-1 aggregate (red) vs. monomer (green) fluorescence ratio of the BPH-1 cells (Figure 3C). These results indicated that TMJ-12 caused mitochondria dysfunction and triggered the mitochondrial apoptotic pathway.

Western blot analysis of several apoptosis- and cell cycle-related proteins revealed that TMJ-12 downregulated the expression of Caspase-3 but increased the cleavage (activation) of this caspase, thereby inducing the cleavage of poly (ADP-ribose) polymerase (PARP) (Figure 4A, B). The ratio of Bax/Bcl-2 was markedly increased in the TMJ-12-treated cells, and the level of cytochrome C in the mitochondria of these cells also increased.

## TMJ-12 inhibits activation of the PI3K/AKT signaling pathway

Several studies have demonstrated that the PI3K/AKT signaling pathway is closely associated with the cell cycle and plays a critical role in controlling cell survival/death. Abnormal activation of the PI3K pathway results in disturbances in the control of cell growth and survival, which can contribute toward cells acquiring a competitive growth advantage, metastatic competence, and, frequently, therapeutic resistance[26]. Thus, we next investigated whether TMJ-12 activated the PI3K/AKT pathway.

Western blot analysis of BPH-1 cells indicated that treatment with TMJ-12 reduced the expression levels of PI3K (subunit p110α) and its downstream regulator PDK1, as well as the phosphorylation of AKT at Ser473 (Figure 5A, B). Diminished levels of phosphorylation at Ser2448 of the mTOR protein was also observed. Further investigation indicated that TMJ-12 treatment inhibited the expression of EIF4E, the phosphorylation target of mTOR, whereas the expression of PTEN increased. These data together imply that TMJ-12 may inhibit AKT through the activation of PTEN and the inhibition of PDK1 and PI3K.
The expression and phosphorylation levels of MAPK/P38 and SAPK/JNK, as components of the side pathway of PI3K/AKT signaling[27], were also determined, as these play crucial roles in regulating apoptosis (Figure 5C, D). The results showed that the phosphorylation levels of MAPK/P38 decreased while the protein levels of SAPK/JNK increased in a time-dependent manner.

Finally, unbiased blind docking was used to predict the region involved in binding between TMJ-12 and PTEN. For this purpose, all known DNA-binding domain structures of PTEN as identified by X-ray crystallography (PDB ID: 1D5R) were used. The docking of TMJ-12 with ID5R showed a low binding energy of −9.23 kJ/mol (Figure 6A, B). Both compounds formed similar van der waals interactions with the residuals including Tyr176, Pro169, Arg173, Tyr180, and Tyr177, and the docking results indicated that TMJ-12 can hydrogen bond to Arg173 of PTEN. Also, we used Oroxin B which is the activator of PTEN as a positive control[28] (Figure 6 C, D). In comparison to Oroxin B, TMJ-12 formed more hydrogen bonds with PTEN. These data indicated that TMJ-12 enhanced the activity of PTEN. Thus, the docking analysis findings suggest that TMJ-12 can directly bind with PTEN and may thereby inhibit the PI3K/AKT signaling pathway.

**Discussion**

Natural products have been a rich source of compounds for drug discovery, and natural products continue to enter clinical trials as anticancer and antimicrobial agents[29]. Natural products exhibit diverse structures that correspond to the diversity of their biological functions and binding partners[30]. Our previous study found that TMJ-12, a germacrane sesquiterpenoid extracted from *Carpesium cernuum*, inhibits the proliferation of the cervical cancer cell line, HeLa, and the liver cancer cell line, HepG2[31]. In the present study, TMJ-12 was tested on the benign prostatic hyperplasia cell line, BPH-1.

In this study, we focused on the inhibitory effect of TMJ-12 on the proliferation of BPH-1 cells and explored the mechanisms involved. Both the MTT assay and colony formation assay demonstrated that TMJ-12 has a strong inhibitory effect on the proliferation of BPH-1 cells in a time- and dose-dependent manner. Further, flow cytometry assays showed that TMJ-12 can block the growth of BPH-1 cells in the G2/M phase and promote BPH-1 cell apoptosis.
Previous studies have demonstrated that cell apoptosis occurs mainly through the intrinsic mitochondrial pathway and the extrinsic death receptor pathway. The mitochondrial pathway of apoptosis is known to depend on the activation of caspases, which ultimately results in cell death characterized by cellular shrinkage, chromatin condensation, and membrane blebbing[32]. This pathway is triggered by cellular stress or developmental cues that cause mitochondrial damage, leading to the release of Cytochrome C, apoptosis-inducing factor, and procaspase-9 into the cytosol and the formation of a complex termed the apoptosome[33,34]. Our data showed that TMJ-12 likely induces mitochondria-mediated apoptosis in BPH-1 cells, as treatment with TMJ-12 resulted in reduced mitochondrial membrane potential, increased Bax/Bcl-2 expression ratio, increased level of Cytochrome C released into the cytosol, activation of Caspase-9 (an initiator caspase) such that it could enter the cell and form a complex termed the apoptosome, followed by the release of Caspase-3 and cleavage of PARP.

Many anti-tumor agents inhibit cell replication by blocking the cell cycle at specific checkpoints. CDC25C is one of the key proteins regulating cell entry to the G2/M phase and providing positive feedback to regulate cell mitosis, and CDC25C is known to be activated by CDK1 and Cyclin B1[35,36]. Our study showed a significant decrease in CDC25C, p-CDC25C, CDK2, Cyclin B1, and c-Myc, along with an increase in P53, P21Cip1, and P27Kip1 in BPH-1 cells when treated with TMJ-12. These findings indicated that TMJ-12 may block the growth of BPH-1 cells in the G2/M phase.

The effect of TMJ-12 on the PI3K/AKT signaling pathway was also investigated. The PI3K pathway regulates various cellular processes, such as proliferation, growth, and apoptosis. In this study, we observed that TMJ-12 induced the expression of PTEN and inhibited PI3K/AKT phosphorylation, suggesting that TMJ-12 may be involved in cell cycle arrest and apoptosis (Figure 7). To further investigate whether TMJ-12 affects the PI3K/AKT pathway by regulating PTEN, molecular docking was applied and TMJ-12 was found to exhibit strong affinity toward PTEN in silico.

In conclusion, the present study demonstrated that TMJ-12, which is a compound extracted from *Carpesium cernuum*, offers broad-spectrum antitumor activity against the benign prostatic hyperplasia cell line BPH-1. TMJ-12 was shown to promote BPH-1 cell apoptosis and cell cycle arrest at G2/M. In addition, several key factors along the PI3K/AKT pathway were found to
exhibit significantly altered expression following TMJ-12 treatment, which would have resulted in the increased rates of cell apoptosis observed. Overall, our findings suggest that TMJ-12 may be a promising lead compound for the treatment of benign prostatic hyperplasia.

Acknowledgments

We thank Natasha Beeton-Kempen, Ph.D., from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Author contributions

Zhu. J. G and Li. Y. M designed the research. Chen. X. Y and Song. J. R performed the research. Chen. X. Y, Rao. Q and Yuan. D. B analyzed the data. Chen. X .Y and Zhu. G. H wrote the paper. Yan. C and Feng. S. H extracts and separates compound incaspitolide A from *Carpesium cernuum*.

Data Availability Statement

All data can be obtained by the corresponding author.

Conflict of interest

The authors declare that they have no conflicts of interest.

Finding

This work was supported by grants from the National Natural Science Foundation of China (81872772, 81960546, 81700169 and U1812403), The Science and Technology Department of Guizhou Province (QKHJC[2018]1409, QKHZC [2019]2762, QKHPTRC[2020]5008, QKHZC[2020]4Y203), The 100 Leading Talents of Guizhou Province (fund for Y. M. L). P2018-KF11, QZYY-2019-022, The High-level innovative talent project of Guizhou Province in 2018 ([2018]5639), The Science and Technology Plan Project of Guizhang in 2019 ([2019]2-15), Science and Technology Plan Project of Guizhou Province in 2019 ([2019]1203), Science and Technology Department of Guizhou Province (QKHJC [2016]1002).

Abbreviations
BPH, Benign prostatic hyperplasia; PI3K, Phosphatidylinositol 3-kinase; AKT, protein kinase B; PDK1, 3-phosphoinositide-dependent protein kinase 1; CDK1, cyclin-dependent kinase 1; 4EBP14, E-binding protein 1; p70S6K, ribosomal p70S6 kinase; PTEN, phosphatase and tensin homolog deleted on chromosome 10; BPH-1, benign prostatic hyperplasia cell line; PARP, poly(ADP-ribose) polymerase;

References
1 He, W., Wang, X., Zhan, D., Li, M., Wang, Q. and Liu, J. et al. (2021) Changes in the expression and functional activities of Myosin II isoforms in human hyperplastic prostate. Clin Sci (Lond), 10.1042/CS20201283
2 Hellwege, J.N., Stallings, S., Torstenson, E.S., Carroll, R., Borthwick, K.M. and Brilliant, M.H. et al. (2019) Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network. Sci Rep 9, 6077, 10.1038/s41598-019-42427-z
3 Langan, R.C. (2019) Benign Prostatic Hyperplasia. Prim Care 46, 223-232, 10.1016/j.pop.2019.02.003
4 Edwards, J.L. (2008) Diagnosis and management of benign prostatic hyperplasia. Am. Fam. Physician 77, 1403-1410
5 Andriole, G.L. and Kirby, R. (2003) Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. 44, 82-88, 10.1016/s0302-2838(03)00198-2
6 Thomas, D., Chughtai, B., Kini, M. and Te, A. (2017) Emerging drugs for the treatment of benign prostatic hyperplasia. Expert Opin Emerg Drugs 22, 201-212, 10.1080/14728214.2017.1369953
7 Suzuki, M., Ito, Y., Fujino, T., Abe, M., Umegaki, K. and Onoue, S. et al. (2009) Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol. Sin. 30, 227-281, 10.1038/aps.2009.1
8 Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y. and Mills, G.B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004, 10.1038/nrd1902
9 Sun, M., Hillmann, P., Hofmann, B.T., Hart, J.R. and Vogt, P.K. (2010) Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit
10 Fayard, E., Xue, G., Parcellier, A., Bozulic, L. and Hemmings, B.A. (2010) Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. *Curr Top Microbiol Immunol* **346**, 31-56, 10.1007/82_2010_58

11 Pei, X.D., He, Z.L., Yao, H.L., Xiao, J.S., Li, L. and Gu, J.Z. et al. (2021) 6-Shogaol from ginger shows anti-tumor effect in cervical carcinoma via PI3K/Akt/mTOR pathway. *Eur. J. Nutr.*, 10.1007/s00394-020-02440-9

12 Liu, X., Powlas, J., Shi, Y., Oleksijew, A.X., Shoemaker, A.R. and De Jong, R. et al. (2004) Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth. *Anticancer Res.* **24**, 2697-2704

13 Mills, C.C., Kolb, E.A. and Sampson, V.B. (2018) Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy. *Cancer Res.* **78**, 320-325, 10.1158/0008-5472.CAN-17-2782

14 Wendel, H.G., De Stanchina, E., Fridman, J.S., Malina, A., Ray, S. and Kogan, S. et al. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. *Nature* **428**, 332-337, 10.1038/nature02369

15 Podsypanina, K., Lee, R.T., Politis, C., Hennessy, I., Crane, A. and Puc, J. et al. (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+-/- mice. *Proc Natl Acad Sci USA* **98**, 10320-10325, 10.1073/pnas.171060098

16 Degraffenried, L.A., Fulcher, L., Friedrichs, W.E., Grunwald, V., Ray, R.B. and Hidalgo, M. (2004) Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. *Ann. Oncol.* **15**, 1510-1516, 10.1093/annonc/mdh388

17 Zhang, J.P., Wang, G.W., Tian, X.H., Yang, Y.X., Liu, Q.X. and Chen, L.P. et al. (2015) The genus Carpesium: a review of its ethnopharmacology, phytochemistry and pharmacology. *J. Ethnopharmacol.* **163**, 173-191, 10.1016/j.jep.2015.01.027

18 Chung, I.M., Seo, S.H., Kang, E.Y., Park, W.H., Park, S.D. and Moon, H.I. (2010) Antiplasmodial activity of isolated compounds from Carpesium divaricatum. *Phytother. Res.* **24**, 451-453, 10.1002/ptr.2881

19 Kun, W. (2019) Study on anti-prostatic hyperplasia activity and mechanism of Carpesium cernuum. *Nat Prod Res Dev*
20 Beekman, A.C., Woerdenbag, H.J., van Uden, W., Pras, N., Konings, A.W. and Wikstrom, H.V. et al. (1997) Structure-cytotoxicity relationships of some helenanolide-type sesquiterpene lactones. *J. Nat. Prod.* 60, 252-257, 10.1021/np960517h

21 Chen Yana, W.Z.A.M. (2018) Carpescernolides A and B, rare oxygen bridge-containing sesquiterpene lactones from Carpesium cernuum. *Tetrahedron Lett.*

22 Zhang, Y., Yang, J., Wen, Z., Chen, X., Yu, J. and Yuan, D. et al. (2020) A novel 3',5'-diprenylated chalcone induces concurrent apoptosis and GSDME-dependent pyroptosis through activating PKCdelta/JNK signal in prostate cancer. *Aging (Albany NY)* 12, 9103-9124, 10.18632/aging.103178

23 Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K. and Goodsell, D.S. et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* 30, 2785-2791, 10.1002/jcc.21256

24 Trott, O. and Olson, A.J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* 31, 455-461, 10.1002/jcc.21334

25 Bender, C.E., Fitzgerald, P., Tait, S.W., Llambi, F., Mestay, G.P. and Tupper, D.O. et al. (2012) Mitochondrial pathway of apoptosis is ancestral in metazoans. *Proc Natl Acad Sci U S A* 109, 4904-4909, 10.1073/pnas.1120680109

26 Mayer, I.A. and Arteaga, C.L. (2016) The PI3K/AKT Pathway as a Target for Cancer Treatment. *Annu. Rev. Med.* 67, 11-28, 10.1146/annurev-med-062913-051343

27 Sun, X.M., Macfarlane, M., Zhuang, J., Wolf, B.B., Green, D.R. and Cohen, G.M. (1999) Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. *J. Biol. Chem.* 274, 5053-5060, 10.1074/jbc.274.8.5053

28 Yan, T., Wang, X., Wei, G., Li, H., Hao, L. and Liu, Y. et al. (2021) Exosomal miR-10b-5p mediates cell communication of gastric cancer cells and fibroblasts and facilitates cell proliferation. *J. Cancer* 12, 2140-2150, 10.7150/jca.47817

29 Harvey, A.L., Edrada-Ebel, R. and Quinn, R.J. (2015) The re-emergence of natural products for drug discovery in the genomics era. *Nat. Rev. Drug Discov.* 14, 111-129, 10.1038/nrd4510

30 Yang, S., Chen, J., Guo, Z., Xu, X.M., Wang, L. and Pei, X.F. et al. (2003) Triptolide inhibits the growth and metastasis of solid tumors. *Mol. Cancer Ther.* 2, 65-72

31 Zhang, T., Si, J.G., Zhang, Q.B., Ding, G. and Zou, Z.M. (2016) New Highly Oxygenated
Germacranolides from Carpesium divaricatum and their Cytotoxic Activity. *Sci Rep* **6**, 27237, 10.1038/srep27237

32 Green, D.R. (2019) The Coming Decade of Cell Death Research: Five Riddles. *Cell* **177**, 1094-1107, 10.1016/j.cell.2019.04.024

33 Chipuk, J.E. and Green, D.R. (2005) Do inducers of apoptosis trigger caspase-independent cell death? *Nat Rev Mol Cell Biol* **6**, 268-275, 10.1038/nrm1573

34 Deng, J. (2017) How to unleash mitochondrial apoptotic blockades to kill cancers? *Acta Pharm Sin B* **7**, 18-26, 10.1016/j.apsb.2016.08.005

35 Perdiguero, E. and Nebreda, A.R. (2004) Regulation of Cdc25C activity during the meiotic G2/M transition. *Cell Cycle* **3**, 733-737

36 Wang, T., Liu, C. and Jia, L. (2018) The roles of PKCs in regulating autophagy. *J Cancer Res Clin Oncol* **144**, 2303-2311, 10.1007/s00432-018-2731-4

**Figure Legends**

**Figure 1.** Compound TMJ-12 inhibits the proliferation of BPH-1 cells. (A) Chemical structure of compound TMJ-12 extracted from *Carpesium cernuum*. (B) BPH-1 cells were treated with various concentrations of TMJ-12 for 12, 48, or 72 h, and the effect on cell viability was determined with the MTT assay. (C) The IC50 value (μM) of TMJ-12 toward the BPH-1 cells was determined. (D, E) The number of colonies formed was counted and analyzed using crystal violet staining. Data represent the mean ± SD, n = 3. **P < 0.01 vs. the control group.

**Figure 2.** TMJ-12 induces G2/M phase cell cycle arrest of BPH-1 cells. (A) The cell cycle phase distribution of BPH-1 cells treated with various concentrations of TMJ-12 for 24 h or 48 h was determined using propidium iodide. The percentage of the cell cycle distribution at the G1, S, and G2 phases are shown on the right as the means ± SD, n = 3. (B, C) BPH-1 cells were exposed to TMJ-12 (8 μM or 16 μM) for 24 h, and the protein expression levels of core factors associated with cell cycle progression were measured by western blotting. GAPDH was used as the loading control. Data represent the mean ± SD, n = 3. *P < 0.05, **P < 0.01 vs. the control group; ns, not significant.

**Figure 3.** TMJ-12 induces the apoptosis of BPH-1 cells via the mitochondrial apoptotic pathway. (A) BPH-1 cells were treated with TMJ-12 for 24 h or 48 h, stained with annexin
V-FITC and propidium iodide, and then analyzed by flow cytometry. The bar plot indicates the percentage of total apoptosis in each treatment group. Data represent the mean ± SD, n = 3. **P < 0.01 vs. the control group. (B) BPH-1 cells were stained with Hoechst 33258 and examined under a fluorescence microscope (magnification, ×200; scale bar, 0.01 mm). (C) BPH-1 cells were treated with TMJ-12 for 24 h, stained with the fluorescent dye, JC-1, and the mitochondrial membrane potential was then examined by fluorescence microscopy (magnification, ×200; scale bar, 0.01 mm). The distributions of the red (JC-1 aggregates) versus green (JC-1 monomers) fluorescence in the BPH-1 cells are shown.

Figure 4. Effect of TMJ-12 on the expression of proteins involved in the apoptosis of BPH-1 cells. (A, B) BPH-1 cells were treated with TMJ-12 for 24 h and then subjected to western blot analysis using antibodies against various known apoptotic factors. GAPDH was used as the loading control. Data represent the mean ± SD, n = 3. *P < 0.05, **P < 0.01 vs. the control group.

Figure 5. The inhibitory effect of TMJ-12 on BPH-1 cells is mediated by activation of the PI3K/AKT signaling pathway. (A–D) BPH-1 cells were treated with various concentrations of TMJ-12 for 24 h, and the protein expression levels of various factors along the PI3K/AKT signaling pathway were analyzed by western blotting. GAPDH was used as the loading control. Data represent the mean ± SD, n = 3. *P < 0.05, **P < 0.01 vs. the control group.

Figure 6. Computational docking analysis of TMJ-12 with the PTEN protein. (A, B) The binding conformation of TMJ-12 in the active side of PTEN and the Schematic diagram representing the PTEN-binding site and proximate affinity of TMJ-12. (C, D) The binding conformation of Otoxin B in the active side of PTEN and Schematic diagram representing the PTEN-binding site and proximate affinity of Otoxin B. Black dots: carbon atoms; blue dots: nitrogen atoms; red dots: oxygen atoms; green dotted lines: hydrogen bonds; red combs: amino acid residues.

Figure 7. Schematic diagram depicting the effect of TMJ-12 on the PI3K/AKT signaling pathway leading to the induction of apoptosis and cell cycle arrest in BPH-1 cells.

Supplementary Figure 1. Representative image of BPH-1 cells treated with TMJ-12 for 48 h (magnification, ×200; scale bar, 0.01 mm), TMJ-12 inhibited the cell viability and proliferation of the BPH-1 cells.
**Figure A:** Chemical structure of the compound.

**Figure B:** Graph showing inhibition rate at 24, 48, and 72 hours.

**Figure C:** Table showing IC$_{50}$ values for BPH cell lines at 24, 48, and 72 hours.

| Cell line | IC$_{50}$ (µM) |
|-----------|----------------|
|           | 24 h | 48 h   | 72 h   |
| BPH       | 18.81±0.93 | 10.53±0.91** | 8.02±0.75** |

**Figure D:** Concentration (µM) vs. number of colonies.

**Figure E:** Bar chart showing number of colonies at 24, 48, 72, and 120 hours for different concentrations.
PTEN binding with TMJ-12

PTEN docking with Oroxin B
Supplementary data

Purity analysis of incaspitolide A.

The HPLC of incaspitolide A isolated from *Carpesium cernuum* L.

1.00 mg/ml; 210 mm-254 mm; Chromatographic methanol: H$_2$O = 65:35; 1.00 ml/min Purity:

98.6536%

| peak # | retention time | Concentration | area | height | peak start | peak start | peak end | area% |
|--------|----------------|---------------|------|--------|------------|------------|----------|-------|
| Control | 1 | 3.834 | 0.00000 | 237256 | 8692 | 3.217 | 7.475 | 100.0000 |
| T12 | 1 | 3.831 | 0.00000 | 419903 | 17414 | 3.433 | 6.075 | 11.0329 |
| | 2 | 8.417 | 0.00000 | 3334778 | 170592 | 7.792 | 10.775 | 87.6207 |
| | 3 | 18.989 | 0.00000 | 51243 | 1206 | 18.442 | 19.617 | 1.3464 |

$^1$H NMR spectrum of incaspitolide A in CDCl$_3$ (INOVA 400 MHz).
$^{13}$C NMR spectrum of incaspitolide A in CDCl$_3$ (INOVA 400 MHz).